HIV Clinical Trial
— PACEROfficial title:
Postpartum Adherence Clubs to Enhance Support: the PACER Study
| Verified date | February 2018 |
| Source | Columbia University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The Western Cape province of South Africa (SA) is changing the way it treats pregnant women
with HIV. Now, all HIV-infected pregnant women, regardless of how sick or healthy they are,
will receive antiretroviral treatment (ART) for life ("Option B+"). However, there are few
well-developed models of service delivery to support this change to "Option B+" in the
Western Cape and many parts of the continent.
The parent study -- Strategies to Optimize ART Services for Maternal & Child Health
(MCH-ART)-- is testing two clinic-based models of service delivery for Option B+ . To
complement MCH-ART, this study, PACER, will test whether community-based Adherence Clubs are
an effective model for keeping breastfeeding women in HIV care after pregnancy. These clubs
have been used to free up space at ART clinics by moving stable HIV+ patients to
community-based services, but they have not been studied as an effective strategy among
breastfeeding women after delivery. PACER seeks to address this gap.
| Status | Completed |
| Enrollment | 258 |
| Est. completion date | October 31, 2016 |
| Est. primary completion date | October 31, 2016 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Age 18 years or older - Documented HIV-infection according to two finger-prick rapid tests using different test types (per routine protocol in this setting) or documentation of HIV status for those women self reporting HIV diagnosis. - Initiated ART during the antenatal period (during most recent pregnancy) - Within one month postpartum - Currently breastfeeding within one month postpartum - Willingness to return for postnatal study visits - Able to provide informed consent for research - Eligible to receive care at local Adherence Club, based on following local eligibility criteria: 1. Virally suppressed (HIV RNA <1000 copies/mL) per most recent viral load test (conducted during pregnancy) 2. Clinically stable (no active co-morbidity including opportunistic infections) 3. Current resident of a catchment area appropriate for Adherence Club referral - Infants of women enrolled in the study. Exclusion Criteria: - Receipt of any ART services outside the Gugulethu MOU ART service in the postpartum period - Intention to relocate out of Cape Town permanently during the following one year - Any medical, psychiatric or social condition which in the opinion of the investigators would affect the ability to consent and/or participate in the study, including: 1. Refusal to take ART/ARVs 2. Denial of HIV status |
| Country | Name | City | State |
|---|---|---|---|
| South Africa | Gugulethu Community Health Centre | Cape Town | Western Cape |
| Lead Sponsor | Collaborator |
|---|---|
| Columbia University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH) |
South Africa,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Maternal retention | Proportion of mothers retained in HIV care and adhering to ART at 12 months postpartum | 12 months | |
| Secondary | Maternal Loss to Follow-up | Proportion of women who are lost to follow-up on ART at 12 months postpartum. | 12 months | |
| Secondary | Maternal Viral Suppression | Proportion of women with viral suppression at the end of the breastfeeding period. | 12 months | |
| Secondary | Infant HIV diagnosis | Proportion of infants receiving proper HIV diagnosis at 12 months postpartum | 12 months | |
| Secondary | Infant vaccination | Proportion of infants receiving proper vaccinations at 12 months postpartum | 12 months | |
| Secondary | Mother-to-child transmission | Rate of HIV transmission from mother-to-child | 12 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
| Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
| Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
| Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
| Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
| Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
| Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
| Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
| Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
| Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
| Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
| Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
| Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
| Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
| Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
| Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
| Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
| Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |